1. Which of the following statements is most accurate?
A. HIV-2 is associated with higher viral load levels, slower rates of CD4 decline, and slower rates of clinical progression, as compared with HIV-1. B. HIV-2 is associated with higher viral load levels, faster rates of CD4 decline, and faster rates of clinical progression, as compared with HIV-1. C. " HIV-2 is associated with lower viral load levels, faster rates of CD4 decline, and faster rates of clinical progression, as compared with HIV-1. " D. HIV-2 is associated with lower viral load levels, slower rates of CD4 decline, and slower rates of clinical progression, as compared with HIV-1.2. Which of the following statements is most accurate?
A. HIV-infected women, 21 – 29 years old, should have a baseline Pap test at the time of initial diagnosis with HIV. B. HIV-infected women, 21–29 years old, should not have a baseline Pap test at the time of initial diagnosis with HIV. C. HIV-infected women, 30–35 years old, should have a baseline Pap test at the time of initial diagnosis with HIV. D. HIV-infected women, 36–42 years old, should have a baseline Pap test at the time of initial diagnosis with HIV.3. Inactivated vaccines are generally not safe or acceptable in HIV-infected individuals.
A. True B. False4. The preferred treatment regimen for latent tuberculosis infections in HIV-positive patients is most likely to include which of the following doses of Isoniazid?
A. Isoniazid 300 mg daily B. Isoniazid 300 mg twice daily C. Isoniazid 300 mg weekly D. Isoniazid 600 mg twice weekly5. Deferring ART until CD4 counts decline puts individuals at risk of AIDS-defining conditions and has been associated with higher risk of morbidity and mortality.
A. True B. False6. Which of the following statements is most accurate?
A. Avoid the use of abacavir-containing NRTI backbone combinations in chronic hepatitis C co-infected patients unless combined with effective hepatitis antiviral therapy. B. Avoid the use of abacavir-containing NRTI backbone combinations in chronic hepatitis C co-infected patients over the age of 35. C. Avoid the use of abacavir-containing NRTI backbone combinations in chronic hepatitis B co-infected patients unless combined with effective hepatitis antiviral therapy. D. Avoid use of abacavir-containing NRTI backbone combinations in chronic hepatitis B co-infected patients over the age of 65.7. Which of the following statements is most accurate?
A. Raltegravir can be given as 400 mg once daily, or 1200 mg once weekly. B. Raltegravir can be given as 400 mg twice daily, or 1600 mg once daily. C. Raltegravir can be given as 400 mg three times a day, or 1600 mg once daily. D. Raltegravir can be given as 400 mg twice daily, or 1200 mg once daily.8. Which of the following statements is most accurate?
A. Truvada requires renal dosing in patient population with CrCL ≤20 ml/min. B. Truvada requires renal dosing in patient population with CrCL ≤30 ml/min. C. Truvada requires renal dosing in patient population with CrCL ≤50 ml/min. D. Truvada does not require renal dosing.9. A boosted PI-based regimen may be preferred for patients who are at high risk for intermittent therapy.
A. True B. False10. Which of the following adverse effect is most likely to be associated with efavirenz?
A. QTc prolongation B. Spontaneous bleeding C. "Bone marrow suppression" D. Cardiovascular disease11. A 32-year-old male patient has recently been initiated on zidovudine. The patient has questions about zidovudine. Which of the following counseling points should be expressed to the patient regarding zidovudine therapy?
A. Zidovudine may cause gastrointestinal effects. B. Zidovudine may only causes gastrointestinal effects in patients over the age of 35. C. Zidovudine does not typically cause gastrointestinal effects. D. Discontinue therapy 24 hours after experiencing side effects.12. "Virologic failure is the inability to achieve or maintain suppression of viral replication to an HIV RNA level<200 copies."
A. True B. False13. A 28-year-old male patient has recently been initiated on ART. The patient has questions about his ART. Which of the following counseling points should be expressed to the patient regarding ART?
A. Discontinue therapy 24 hours after experiencing side effects. B. Discontinue therapy 48 hours after experiencing side effects. C. Discontinuing ART does not typically affect viral load. D. "Discontinuing ART may result in viral rebound, immune decompensation, and clinical progression. "14. Which of the following statements regarding pneumocystis pneumonia prophylaxis is most accurate?
A. Prophylaxis should begin in HIV-infected patients with a CD4 count <200 cells/μL. B. Prophylaxis should begin in HIV-infected patients with a CD4 count <400 cells/μL. C. Prophylaxis should begin in HIV-infected patients with a CD4 count <600 cells/μL. D. Prophylaxis should begin in HIV-infected patients with a CD4 count <800 cells/μL.15. The first medication choice for toxoplasmosis prophylaxis is TMP-SMX (Bactrim, Septra).
A. True B. FalseCopyright © 2024 Cheap Nursing CEUs
Visit us at https://www.cheapnursingceus.com